NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51655-0410-54 | 51655-0410 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 12, 2021 | In Use | |
50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
70377-0049-13 | 70377-0049 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
51144-0020-01 | 51144-0020 | ENFORTUMAB VEDOTIN | PADCEV | 20.0 mg/2mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
70377-0053-11 | 70377-0053 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
70710-1030-07 | 70710-1030 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
70377-0051-12 | 70377-0051 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
50242-0088-01 | 50242-0088 | ADO-Trastuzumab Emtansine | Kadcyla | 20.0 mg/mL, 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | HER2 | Intravenous | Feb 22, 2013 | In Use | |
70377-0053-12 | 70377-0053 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
69097-0382-73 | 69097-0382 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
60505-4533-02 | 60505-4533 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
59651-0346-01 | 59651-0346 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
68727-0950-02 | 68727-0950 | Zanidatamab-hrii | ZIIHERA | 50.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2 | Intravenous | Nov 20, 2024 | In Use | |
00003-2327-11 | 00003-2327 | Ipilimumab | Yervoy | 5.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Mar 25, 2011 | In Use | |
55513-0160-01 | 55513-0160 | Blinatumomab | Blincyto | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | Intravenous | Dec 18, 2014 | In Use | ||
50242-0917-01 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 18, 2016 | In Use | |
00378-1940-21 | 00378-1940 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
55513-0132-21 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
58468-0357-03 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov 30, 2009 | In Use | |
72606-0011-01 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 3, 2023 | In Use | |
70710-1033-08 | 70710-1033 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
00085-1242-01 | 00085-1242 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Dec 4, 2010 | No Longer Used | ||
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
59651-0344-07 | 59651-0344 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
00480-1244-21 | 00480-1244 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2022 | In Use |
Found 11748 results — Export these results